Survodutide

Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist that mimics oxyntomodulin, a natural gut hormone. It is not approved by any regulatory authority. The dual mechanism is the key differentiator: GLP-1 receptor activity decreases appetite and increases satiety, while glucagon receptor activity acts directly on the liver to stimulate hepatic lipolysis, suppress hepatic fat accumulation, reduce inflammation, improve fibrosis, and may increase energy expenditure.

The SYNCHRONIZE-1 trial (N=725, 76 weeks, obesity without diabetes) is the pivotal phase 3 efficacy study. Mean weight loss reached 16.6% (efficacy estimand) versus 3.2% placebo (P<0.0001), with up to 39.2 lb (17.8 kg) lost from baseline. The co-primary endpoint of proportion achieving at least 5% weight loss was also met. Waist circumference reduction was significant.

SYNCHRONIZE-MASLD (N=216, 48 weeks) tested survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease. Co-primary endpoints both met: 84.2% (efficacy estimand) achieved at least 30% reduction in MRI-PDFF-assessed liver fat versus 24.3% placebo (P<0.0001), and mean body-weight change was 12.2% versus 1.0% placebo (P<0.0001). This liver fat reduction is the most striking result for survodutide and is relevant to MASH as an aging-accelerating condition.

The body composition data from the SYNCHRONIZE-1 MRI substudy is among the most detailed for any GLP-1 or dual agonist. Visceral fat was reduced by up to 34%, liver fat by up to 63.1%, while lean mass changes accounted for no more than 10.8% of total tissue-mass change. This means weight loss was driven predominantly by fat loss with substantial preservation of lean mass. A separate analysis found lean mass loss was not significantly different between survodutide (8.3%) and semaglutide (5.3%) despite greater total weight loss with survodutide. This is a better body composition profile than tirzepatide, where 33.9% of mass lost was lean mass.

A head-to-head phase 2 comparison found similar weight loss with survodutide (17.7%) and semaglutide (15.6%), though this was a small study.

No cardiovascular outcomes trial has been completed. SYNCHRONIZE-CVOT is ongoing (target N=4,935, up to 6,000), designed to test noninferiority of survodutide versus placebo for 5-point MACE. A prespecified subgroup of at least 600 participants with heart failure is included. Phase 2 data showed a hypothetical concern: survodutide increased heart rate by 2.7 bpm (all doses pooled) versus 0.1 bpm with placebo, prompting close cardiovascular monitoring.

Safety is the main concern. Gastrointestinal adverse events (nausea, vomiting, diarrhea, dyspepsia, early satiety) are the most common. A meta-analysis of phase 1-2 trials (4 studies, 980 patients) found significantly higher rates with survodutide versus placebo for vomiting (RR 6.64), nausea (RR 3.3), diarrhea (RR 1.89), and dyspepsia (RR 6.93), and a significantly higher rate of treatment discontinuation due to adverse events (RR 4.53). In SYNCHRONIZE-1, approximately 19% of participants discontinued due to side effects, described in press coverage as outpacing tirzepatide (Zepbound) discontinuation rates roughly threefold. Events of special interest monitored across trials include acute pancreatitis, thyroid malignancies, C-cell hyperplasia, pancreatic cancer, drug-induced liver injury, and acute gallbladder disease.

The dual glucagon/GLP-1 mechanism directly targets ectopic and visceral fat depots with substantial preservation of lean mass, a body-composition profile of particular interest for metabolic healthspan compared with GLP-1-only agonists. Phase 2 MASH data showed improvements in hepatic inflammation and fibrosis. The glucagon receptor component's proposed effects on hepatic lipolysis, systemic and local inflammation resolution, and potential renal glucagon-receptor-mediated benefits are preclinically described but not yet confirmed in long-term human outcome data.